EMPA REG trial outcomes for T2D and CV disease patients

Document ID: PC-AE-101741

02/06/2023

Author: Boehringer Ingelheim


EMPA REG trial outcomes for T2D and CV disease patients

123,000
Views

100k 340

Related content

 
PC-AE-101741
Production date: June 2023